Physician profile
Peter B Rintels
NPI 1871577999
$2,047.65
in general payments reported to CMS, 2019-2025
37 companies · $50.02 in 2025
The $50.02 reported for 2025 was less than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,371 · 2020: $155 · 2021: $41.08 · 2022: $34.09 · 2023: $38.94 · 2024: $358 · 2025: $50.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $425 · Education: $21.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $425.40 |
| Education | $21.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $238.05 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $166.83 | 2019-2023 | Reblozyl |
| Alexion Pharmaceuticals, INC. | $131.71 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $120.77 | 2019 | |
| Abbvie INC. | $109.10 | 2019-2024 | |
| Celgene Corporation | $101.18 | 2019-2021 | |
| Eisai INC. | $82.98 | 2024-2025 | |
| Astellas Pharma US INC | $72.65 | 2019-2020 | |
| Rigel Pharmaceuticals, INC. | $70.19 | 2019-2024 | Tavalisse, Rezlidhia |
| Pfizer INC. | $69.57 | 2019-2025 | |
| Genentech USA, INC. | $55.84 | 2019 | |
| Dendreon Pharmaceuticals LLC | $54.55 | 2019-2024 | Provenge |
| Seagen INC. | $50.14 | 2019 | |
| Glaxosmithkline, LLC. | $49.37 | 2024 | Ojjaara |
| Tesaro, INC. | $48.57 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $47.96 | 2024 | |
| Octapharma USA, INC. | $47.85 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $46.94 | 2019-2024 | |
| Ipsen Biopharmaceuticals, INC | $38.29 | 2019 | |
| Gilead Sciences, INC. | $37.07 | 2019 | |
| Genzyme Corporation | $35.96 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $35.87 | 2019 | |
| Merck Sharp & Dohme LLC | $34.13 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $31.44 | 2019 | |
| Mylan Institutional INC. | $29.11 | 2019 | |
| Incyte Corporation | $28.24 | 2019-2020 | |
| Shire North American Group INC | $27.37 | 2019 | |
| Amgen INC. | $26.86 | 2019 | |
| Aurobindo Pharma USA, INC. | $24.36 | 2019-2020 | |
| Helsinn Therapeutics (U.S.), INC. | $20.14 | 2019 | |
| Amag Pharmaceuticals, INC. | $19.50 | 2019 | |
| Lilly USA, LLC | $17.65 | 2020 | |
| Progenics Pharmaceuticals, INC. | $17.63 | 2023 | Pylarify |
| Emd Serono, INC. | $17.48 | 2019 | |
| Kite Pharma, INC. | $16.52 | 2020 | |
| Puma Biotechnology, INC. | $15.53 | 2019 | |
| Heron Therapeutics, INC. | $10.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Rintels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.